signal, free of contrast enhancement and mass effect. Furthermore, the disease usually begins in the parieto-occipital white matter and spreads forward. The intensity of contrast enhancement and the distribution of lesions in our patient virtually exclude progressive multifocal leukoencephalopathy as a diagnosis.
CNS lymphoma can affect leptomeninges and brain parenchyma simultaneously. In our patient, the magnetic resonance scan was similar to that in patients with primary CNS lymphoma, in the context of human immunodeficiency virus and the post-transplant lymphoproliferative disorders. In these patients, multiple lesions are common, and some may have a variable contrast enhancement. 5 In contrast, direct involvement of the brain parenchyma by leukemia is uncommon and typically occurs as a chloroma or as isolated leukemic nodules.
A high clinical suspicion augmented by sensitive radiologic studies and the use of stereotactic brain biopsy should facilitate early diagnosis of CNS toxoplasmosis, enable timely treatment, and avoid potentially toxic empiric therapy. 8 The recent application of polymerase chain reaction to amplify Toxoplasma DNA may enhance the diagnostic process further. 9 Although prophylactic antibiotics reduce the risk in seropositive patients, the infrequent occurrence of the disease does not warrant uniform application to all patients. 
Influence of bacterial endotoxin on the allogenicity of human endothelial cells
In former times the endothelium has been judged as a simple barrier between the blood and surrounding tissues. However, data from the last decade provide accumulating evidence that there is a close interaction between immunological effector cells and the vasculature in various physiological and inflammatory processes. In particular, endothelial cells (EC) have been identified as allogeneic targets for proliferative immune responses 1 as well as for cytotoxic T lymphocytes. 2 In addition, allogeneic monocytes were found to induce apoptosis in EC through the action of transmembrane TNF-␣. 3, 4 These cytotoxic mechanisms may contribute to the pathophysiology of various complications following BMT that are associated with EC damage or malfunction. 5 There is increasing evidence that pretransplant conditioning regimens, including total body irradiation and cytotoxic chemotherapy, may contribute to an activation of the recipients' endothelium resulting in early inflammatory processes, 6 for example, through the increased expression of adhesion molecules and MHC complexes. Also, the conditioning-mediated influx of bacterial toxins like lipopolysaccharide (LPS) across damaged mucosal barriers can cre- + cytotoxic T lymphocytes: enhancement by bacterial LPS. Adherence-selected 7 lymphocytes were stimulated with irradiated (40 Gy) HUVEC and interleukin 2 (50 U/ml) for 7 days. At day 6 EC from the same umbilical cord were either left untreated (᭺) or incubated with LPS (10 ng/ml, ) for 24 h and used as targets in a standard 51 Cr release assay. E/T ratio = effector:target ratio. This is a representative of four independent experiments. (b) The neutralization of MHC class I on the target cells abrogates allocytotoxic lysis of EC. EC were treated as given for (a) and additionally coincubated with hybridoma supernatants of the anti-MHC class I mAb w6/32 for 2 h prior to the assay (᭜ One day prior to the assay, HUVEC targets from the same umbilical cord were either left untreated or incubated with a clinically relevant dose of LPS (10 ng/ml) for 24 h. Previous studies revealed that 10 ng/ml is the minimally required dose for biological effects on EC. 8 The cytotoxic capacity of the stimulated T lymphocytes was assessed in a standard 51 Cr release assay (Na 2 CrO 4 ; NEN Du Pont, Dreieich, Germany), as is shown in Figure 1a . The allogeneic effector lymphocytes recognized unstimulated HUVEC as cytotoxic targets (23% specific lysis at an effector/target (E/T) ratio of 20). Interestingly, preincubation of target cells with LPS led to an almost two-fold increase in cytolysis (38% specific lysis). To prove that the lysis of EC was indeed due to an MHC class I-restricted T cell recognition, EC were additionally coincubated with a neutralizing mAb against MHC class I (w6/32; ATCC, Rockville, MD, USA) prior to the assay. Neutralizing class I led to an almost complete loss of the cytotoxic activity against both untreated (Figure 1b) and LPS-treated (not shown) target cells, thus excluding the possibility that lysis of EC was the result of a lymphokine-activated killer activity. As a control, an irrelevant isotype-matched mAb did not affect EC lysis (not shown).
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These findings suggest an additional pathway for enhancement of LPS-mediated EC toxicity by increasing allogenicity. They provide further evidence for the interaction of non-specific inflammation and specific allorecognition in the setting of BMT as well as solid organ transplantation.
The investigation of conditioning regimens, including irradiation and chemotherapy, for their ability to elicit an anti-endothelial immune response is currently under investigation in our laboratory. 
Clarification on the use of CEPRATE Stem Cell Concentration System and CEPRATE T Cell Depletion System
In the recent letter from Hale and Waldmann 1 there appears to be some confusion about CE (Conformité Européenne) marking and FDA approval of the CEPRATE ® SC Stem Cell registered Concentration System. CE marking and FDA approval for medical devices are given by two independent authorities based on different criteria and have legal force only in their respective territories. This approval system is different from the system used for drugs. In order to receive the CE marking, the manufacturer must demonstrate that the device is in compliance with the Medical Device Directive. 2 In brief, the Medical Device Directive requires that the manufacturer demonstrates that the devices will not compromise the safety and health of patients and it achieves the performance intended and claimed by the manufacturer. In order to receive FDA approval, the manufacturer must demonstrate that the device is safe and provides a clinical benefit.
In Europe, the CEPRATE SC Stem Cell Selection System and the CEPRATE TCD T cell Depletion System have been granted the CE marking. The CEPRATE SC System is indicated for the positive selection of CD34 + cells (hematopoietic progenitor cells) from bone marrow or mobilized peripheral blood. Data from published studies were provided in the dossier submitted to the notified body demonstrating that positive selection of CD34 + cells using the CEPRATE SC System results in a mean 2.5 to 3 log reduction in T cells 3, 4 and/or a 2 log or greater reduction in tumor cells.
The CEPRATE TCD System is indicated for a supplementary depletion of T cells from a CD34 selected population. Data were provided demonstrating that the CEPRATE TCD System results in an additional log of T cell depletion.
In the United States, the CEPRATE SC Stem Cell Selection System is approved by the FDA for the positive selection of CD34 + cells (hematopoietic progenitor cells) from bone marrow to reduce the toxicities associated with infusion of bone marrow. 5 CellPro has submitted additional data to include an indication for the use of peripheral blood. These data demonstrate that the positive selection of PBSC results in a 3 log reduction in tumor cells. All of the labeling and literature that CellPro Incorporated provides to customers in Europe and the United States is consistent with the medical device approvals in the respective territories.
Additional studies sponsored by CellPro are in progress to confirm the clinical utility of the CEPRATE SC System for tumor cell purging in the autologous transplantation and of the CEPRATE SC and TCD Systems used in the allogeneic setting. The large number of presentations done at scientific meetings, despite the fact that neither European nor United States regulatory agencies restrict the use of approved products by clinicians, confirms the awareness of the transplant groups of the need for supplementary clinical data. 
